The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment ...
OKYO Pharma Limited has filed its annual report on Form 20-F for the fiscal year ended March 31, 2026, with the US Securities ...
New real-world data from ASRS 2026 show nearly 40% of wet AMD patients go 180+ days without anti-VEGF treatment within a year ...
Louie Cai, MD: Manual prescreening for clinical trials is very labor intensive, taking as long as 30 minutes to an hour per ...
OPTIC data showed a single injection of Ixo-vec gene therapy cut annualized anti-VEGF injections 87%, with sustained ...
Microsecond green laser (520 nm; Norlase) improved visual acuity and reduced macular thickness in eyes with chronic central ...
Danon disease has been misclassified as cone dystrophy, cone-rod dystrophy, or retinitis pigmentosa; distinguishing features include the absence of optic disc pallor, bone-spicule pigmentation, and a ...
Awh, MD, FASRS, presented 2-year data at ASRS 2026 showing 4D-150 gene therapy cut anti-VEGF injection burden in wet AMD, ...
Two-year PRISM results show 4D-150 gene therapy sustains wet AMD vision while cutting anti-VEGF injections up to 87%, with ...
REMAIN data show MCO-010 optogenetic therapy delivered durable ~3-line vision gains in retinitis pigmentosa regardless of ...
Presenters highlight clinical insights and lessons from recent trial data and surgical experience On efficacy, Regillo said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results